Dr. Dandoy on TMA Risk After Pediatric Allogeneic Stem Cell Transplant

Christopher E. Dandoy, MD, MSc, assistant professor of pediatrics at Cincinnati Children’s Hospital, says that patients undergoing allogeneic stem cell transplant are at high-risk of developing thrombotic microangiopathy (TMA).

TMA occurs in 30% of these patients and can occur as early as 7 days after transplant. When it is identified to be present, the patient can be properly treated right away, Dandoy notes.

Tools from these data presented at the 2019 Transplantation & Cellular Therapy Meetings as well as tools from other data can be used to identify these patients even earlier.

<<< 2019 Transplantation and Cellular Therapy Meetings